HALISTER: Gilead 4Q Sovaldi Rev. Misses Est.; Shares Fall

Gilead 4Q Sovaldi Rev. Misses Est.; Shares Fall

(Bloomberg) -- Gilead 4Q Sovaldi rev. $541m, est. $595.8m (Bloomberg data)
  • 4Q adj. EPS $2.70, est. $2.61 (range $2.36-$2.87)
  • 4Q rev. $7.32b, est. $7.16b (range $6.66b-$7.62b)
  • 4Q Harvoni rev. $1.64b, est. $1.60b (Bloomberg News)
  • 4Q Truvada rev. $868m, est. $849.5m (Bloomberg data)
    • 4Q Epclusa Rev. $1.05b, est. $880.9m (average of 11)
    • 4Q Atripla rev. $607m, est. $610.4m (average of 13)
    • 4Q Genvoya rev. $563m, est. $559.1m (average of 10)
    • 4Q Stribild rev. $387m, est. $401.7m
    • 4Q Viread rev. $324m, est. $296.4m (average of 13)
    • 4Q Letairis rev. $226m, est. $210.1m
    • 4Q Ranexa rev. $210m, est. $172.3m
    • 4Q Zydelig rev. $39m, est. $41.2m (average of 13)
  • Sees FY17 product sales $22.5b to $24.5b
  • Sees Yr Hcv Product sales $7.5b-$9b
NOTE:
  • Shares down 3.6% since earnings release to $70.50 on 65,381 shares traded
  • 18 buys, 12 holds, 0 sells before today
  • Call 4:30pm (NY time), 877-359-9508 pw 43555238
Statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
GILD US (Gilead Sciences Inc)

To de-activate this alert, click here

UUID: 7947283